PSI 7851

Drug Profile

PSI 7851

Alternative Names: PSI-7851

Latest Information Update: 25 Aug 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmasset
  • Class Antivirals; Cell therapies; Nucleosides; Pyrimidine nucleosides
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 25 Aug 2010 Discontinued - Phase-I for Hepatitis C in USA (PO)
  • 31 Jul 2009 Interim efficacy and adverse events data from a phase Ib trial in hepatitis released by Pharmasset
  • 09 Jun 2009 Interim adverse events data from a phase Ia trial in healthy volunteers, and pharmacokinetic data, released by Pharmasset
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top